RGNX
REGENXBIO Inc.
Overview
REGENXBIO Inc is a Healthcare company operating in Biotechnology with a $468.9M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1414 Q&A exchanges
- Q4 FY2025Earnings2026-03-0513 Q&A exchanges
- Q3 FY2025Earnings2025-11-0617 Q&A exchanges
- Q1 FY2025Earnings2025-05-1323 Q&A exchanges
- Q4 FY2024Earnings2025-03-1322 Q&A exchanges
- Q3 FY2024Earnings2024-11-0623 Q&A exchanges
- Q2 FY2024Earnings2024-08-0127 Q&A exchanges
- Q1 FY2024Earnings2024-05-0812 Q&A exchanges
- Q4 FY2023Earnings2024-02-2721 Q&A exchanges
- Q3 FY2023Earnings2023-11-0815 Q&A exchanges
- Q2 FY2023Earnings2023-08-0221 Q&A exchanges
- Q1 FY2023Earnings2023-05-0313 Q&A exchanges
- Q4 FY2022Earnings2023-02-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0311 Q&A exchanges
- Q2 FY2022Earnings2022-08-0522 Q&A exchanges
- Q1 FY2022Earnings2022-05-049 Q&A exchanges
- Q4 FY2021Earnings2022-03-0114 Q&A exchanges
- Q3 FY2021Earnings2021-11-028 Q&A exchanges
- Q2 FY2021Earnings2021-08-098 Q&A exchanges
- Q1 FY2021Earnings2021-05-057 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $0.12—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $0.12 | — | — | — | — | EODHD |
Source: EODHD. RGNX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks RGNX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.53 | $0.60 | -11.1% | -0.3% | +2.1% |
| Q4 FY2026 | $0.44 | $0.54 | -18.6% | -9.0% | -6.1% |
| Q3 FY2026 | $0.39 | $0.41 | -5.3% | +1.8% | -1.0% |
| Q2 FY2026 | $0.47 | $0.57 | -18.1% | -8.1% | -10.6% |
| Q1 FY2025 | $0.47 | $0.49 | -3.8% | -7.5% | -6.9% |
| Q4 FY2025 | $0.50 | $0.59 | -14.9% | -9.2% | -9.7% |
| Q3 FY2025 | $0.45 | $0.49 | -7.3% | -0.7% | -2.1% |
| Q2 FY2025 | $0.63 | $0.75 | -15.9% | -4.1% | -3.7% |
| Q1 FY2024 | $0.54 | $0.61 | -11.2% | -2.7% | -4.0% |
| Q4 FY2024 | $0.72 | $0.77 | -6.4% | -6.8% | -7.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Curran SimpsonCEO1 yr 5 mo8 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Mitchell ChanCFO1 yr 5 mo4 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
- Craig MalzahnChief Technology Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
- Steve PakolaChief Medical Officer1 yr 5 mo18 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
- Patrick J ChristmasChief Strategy & Legal Officer10 mo19 callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Olivier DanosChief Scientific Officer1 mono recorded callsFormerSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RGNX.
$ curl https://api.spokenalpha.com/v1/companies/RGNXFAQ
Frequently asked about RGNX
Where can I find REGENXBIO Inc.'s (RGNX) earnings call transcripts?
Spoken Alpha indexes RGNX's earnings call transcripts at https://spokenalpha.com/companies/RGNX. Each call links to attributed speakers and parsed analyst Q&A. REGENXBIO Inc.'s own investor relations page is at https://ir.regenxbio.com/.
When was REGENXBIO Inc.'s most recent earnings call?
REGENXBIO Inc. (RGNX) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
What sector is RGNX in?
REGENXBIO Inc. (RGNX) operates in the Healthcare sector (Biotechnology industry).